x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012037
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Applications | WB, IP |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu440 of human FTCD protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | FTCD |
| UniProt No. | O95954 |
| Gene ID | 10841 |
| Gene Description | Formimidoyltransferase-cyclodeaminase catalyzes two key consecutive reactions in the histidine degradation pathway and links histidine catabolism to one-carbon metabolism. It converts tetrahydrofolate to 5, 10-methenyl-THF. Loss of FTCD decreases the sensitivity of cancer cells to chemotherapeutic drug methotrexate, an inhibitor of dihydrofolate reductase. DHFR reduces dihydrofolate to tetrahydrofolate, an essential cofactor for nucleotide biosynthesis. Lack of FTCD leads to higher levels of tetrahydrofolate in methotrexate-treated cells, therefore reducing the effect of methotrexate. Conversely, greater depletion of tetrahydrofolate by FTCD through enhanced histidine degradation pathway may boost the efficacy of methotrexate. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
